The effects of adequate dietary calcium intake in patients with hypoparathyroidism non-adherent to treatment: a prospective randomized controlled trial

dc.contributor.authorid0000-0002-0933-6198
dc.contributor.coauthorCanat, Muhammed Masum
dc.contributor.coauthorDonmez, Cigdem
dc.contributor.coauthorKostek, Hatice
dc.contributor.coauthorKostek, Mehmet
dc.contributor.coauthorKara, Zeynep Mine Yalcinkaya
dc.contributor.coauthorOztuerk, Feyza Yener
dc.contributor.coauthorAltunta, Yuksel
dc.contributor.departmentN/A
dc.contributor.kuauthorBatman, Adnan
dc.contributor.kuprofileDoctor
dc.contributor.schoolcollegeinstituteN/A
dc.contributor.unitKoƧ University Hospital
dc.date.accessioned2025-01-19T10:29:05Z
dc.date.issued2023
dc.description.abstractOBJECTIVE: A significant problem that compels clinicians in the conventional treatment of hypoparathyroidism is patients' non-adherence to treatment. This study aimed to evaluate the effects of adequate Ca intake with dietary recommendations among hypoparathyroidism patients who persistently use Ca supplementation irregularly on plasma Ca and phosphate levels.METHODS: This prospective, randomized, controlled study was conducted on patients diagnosed with chronic hypoparathyroidism who persistently interrupt Ca supplementation therapy and therefore have a hypocalcemic course. Patients with a total daily Ca intake below 800 mg were randomized. All patients were advised to keep the doses of active vitamin D and Ca supplements they were currently using. The patients in the study group (n=32) were advised to consume 1,000-1,200 mg of Ca daily, and the patients in the control group (n=35) were advised to continue their diet according to their daily habits. After 12 weeks of follow-up, the patients' laboratory values were compared between groups to assess treatment goals.RESULTS: The mean of the total Ca level was 8.56 +/- 0.36 mg/dL in the study group and was found to be significantly higher than that in the control group, which was 7.67 +/- 0.48 mg/dL (p<0.001). The mean serum phosphate and serum Ca-P product levels were significantly higher in the study group (p<0.001) but did not exceed the safe upper limits in any patient.CONCLUSION: A suitable increase in dietary Ca intake could effectively control hypocalcemia in patients with hypoparathyroidism who persistently interrupt the recommended calcium supplementation.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue11
dc.description.openaccessGreen Published, gold
dc.description.publisherscopeInternational
dc.description.volume69
dc.identifier.doi10.1590/1806-9282.20230406
dc.identifier.eissn1806-9282
dc.identifier.issn0104-4230
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85175679079
dc.identifier.urihttps://doi.org/10.1590/1806-9282.20230406
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25827
dc.identifier.wos1098353300001
dc.keywordsHypoparathyroidism
dc.keywordsDietary calcium
dc.keywordsMedication non-adherence
dc.languageen
dc.publisherAssociacao Medica Brasileira
dc.sourceRevista da Associacao Medica Brasileira
dc.subjectMedicine, general and internal
dc.titleThe effects of adequate dietary calcium intake in patients with hypoparathyroidism non-adherent to treatment: a prospective randomized controlled trial
dc.typeJournal Article

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05581.pdf
Size:
384.15 KB
Format:
Adobe Portable Document Format